Emergent Stability Testing for Hiv Adenoviral Vaccine Tender

• Country: USA
• Summary: Emergent Stability Testing for Hiv Adenoviral Vaccine Candidates
• UST Ref No: 139523322
• Deadline: 23 Apr 2026
• Financier: Self Financed
• Purchaser Ownership: Government
• Tender Value: Refer Document
• Notice Type: Tender
• Document Ref. No.: NOI-NIAID-26-0001
• Purchaser's Detail:
  Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.

  Login to see details
• Description:
• Document Type: Notice of Intent to Sole Source
  Solicitation Number: NOI-NIAID-26-0001
  Posted Date: 04/13/2026
  Response Date: 04/23/2026, 12:00 PM EST
  Set Aside: N/A
  NAICS Code: 541714 - RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
  Product Service Code: Q301 - MEDICAL - LABORATORY TESTING
  Contracting Office Address:
  Department of Health and Human Services, National Institutes of Health, National Institute of Allergy & Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852
  Title: Emergent Stability Testing for HIV Adenoviral Vaccine Candidates
  Description:
  THIS IS A NOTICE OF INTENT AND NOT A REQUEST FOR QUOTATIONS
  This notice is published in accordance with Federal Acquisition Regulation (FAR) 5.101(a)(1) requiring the dissemination of information regarding proposed contract actions. This is a Notice of Intent to award a sole source, firm-fixed price purchase order under the authority of 41 U.S.C. 3304(a)(1), as implemented by FAR 13.106-1(b)(2) and 13.501(a) - Only One Responsible Source and No Other Supplies or Service Will Satisfy Agency Requirements and is not a request for competitive proposals.
  The National Institute of Allergy and Infectious Diseases (NIAID), Division of AIDS (DAIDS) intends to negotiate on a sole source basis with Emergent Travel Health Inc., 555 Twin Dolphin Dr, Ste 360, Redwood City, CA 94065-2142. This acquisition will provide maintenance of the Biologics Master File 018816 - Human Immunodeficiency Virus Type 1, Recombinant (Adenovirus Type 4; Ad4Env150KN and Ad4-Env145FL; 1086 clade C Env; A549 Cells) Vaccines, Live Master File (BB-MF 018816).
  BB-MF 018816 was originally established by Emergent under Purchase Order 75N93022PO1224 and contains CMC and nonclinical study information for the HIV-1 Adenovirus Type 4-Vectored (A549 cells) Vaccines, Live, Aqueous (Ad4-HIV). Purchase Order 75N93022PO1224 ended with stability work being transitioned to a testing lab contracte...
• Documents:

 Tender Notice